Therefore, all patients with NSCLC without a contraindication (e.g., autoimmune diseases) or an actionable driver mutation (e.g., epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK], or c‐ros oncogene 1 [ROS1]) should receive a PD(L)1i as part of their first‐line treatment.12 The gene discussed is ALK; the disease is non-small cell lung carcinoma.